Trials / Recruiting
RecruitingNCT06057948
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Phase II Trial of a Bivalent Vaccine With the Immunological Adjuvant OPT-821 (QS-21), in Combination With Randomization of Oral β-glucan, for High-Risk Neuroblastoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 94 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | OPT-821 (QS-21) | Comprised of the immunological adjuvant OPT-821 (QS-21) |
| DIETARY_SUPPLEMENT | oral β-glucan | Participants will be randomized to receive this agent in two different schedules |
Timeline
- Start date
- 2023-09-21
- Primary completion
- 2027-03-21
- Completion
- 2027-03-21
- First posted
- 2023-09-28
- Last updated
- 2026-04-02
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06057948. Inclusion in this directory is not an endorsement.